Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 213-218

  Mantovani, S ^a   Gordon, R ^a   Macmaw, J K ^a   Pfluger, C M M ^b   Henderson, R D ^c   Noakes, P G ^a   McCombe, P A ^b,c   Woodruff, T M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

ALS; C3a; C5a; C5b 9; Complement system; Terminal pathway

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ANAPHYLATOXIN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; AGED; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANAPHYLATOXINS; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 84908513866     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.09.005     Document Type: Article

References (56)

1. Al-Chalabi A., Jones A., Troakes C., King A., Al-Sarraj S., van den Berg L.H. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012, 124:339-352.
2. Babu G.N., Kumar A., Chandra R., Puri S.K., Kalita J., Misra U.K. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem. Res. 2008, 33:1145-1149.
3. Bellavia D., Frada G., Di Franco P., Feo S., Franceschi C., Sansoni P., Brai M. C4, BF, C3 allele distribution and complement activity in healthy aged people and centenarians. J. Gerontol. A: Biol. Med. Sci. 1999, 54:B150-B153.
4. Bellingham M.C. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci. Ther. 2011, 17:4-31.
5. Blokhuis A.M., Groen E.J., Koppers M., van den Berg L.H., Pasterkamp R.J. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013, 125:777-794.
6. Bokisch V.A., Muller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 1970, 49:2427-2436.
7. Brettschneider J., Toledo J.B., Van Deerlin V.M., Elman L., McCluskey L., Lee V.M., Trojanowski J.Q. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE 2012, 7:e39216.
8. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000, 1:293-299.
9. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749.
10. Butovsky O., Siddiqui S., Gabriely G., Lanser A.J., Dake B., Murugaiyan G., Doykan C.E., Wu P.M., Gali R.R., Iyer L.K., Lawson R., Berry J., Krichevsky A.M., Cudkowicz M.E., Weiner H.L. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 2012, 122:3063-3087.
11. Chiu I.M., Phatnani H., Kuligowski M., Tapia J.C., Carrasco M.A., Zhang M., Maniatis T., Carroll M.C. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20960-20965.
12. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001, 2:806-819.
13. Crehan H., Hardy J., Pocock J. Microglia, Alzheimer's disease, and complement. Int. J. Alzheimers Dis. 2012, 2012:983640.
14. Denny K.J., Coulthard L.G., Finnell R.H., Callaway L.K., Taylor S.M., Woodruff T.M. Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. J. Reprod. Immunol. 2013, 97:211-216.
15. Donnenfeld H., Kascsak R.J., Bartfeld H. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol. 1984, 6:51-57.
16. Ember J.A., Sanderson S.D., Hugli T.E., Morgan E.L. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am. J. Pathol. 1994, 144:393-403.
17. Fiala M., Chattopadhay M., La Cava A., Tse E., Liu G., Lourenco E., Eskin A., Liu P.T., Magpantay L., Tse S., Mahanian M., Weitzman R., Tong J., Nguyen C., Cho T., Koo P., Sayre J., Martinez-Maza O., Rosenthal M.J., Wiedau-Pazos M. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflammation 2010, 7:76.
18. Flierl M.A., Stahel P.F., Rittirsch D., Huber-Lang M., Niederbichler A.D., Hoesel L.M., Touban B.M., Morgan S.J., Smith W.R., Ward P.A., Ipaktchi K. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit. Care 2009, 13:R12.
19. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49:171-186.
20. Goldknopf I.L., Sheta E.A., Bryson J., Folsom B., Wilson C., Duty J., Yen A.A., Appel S.H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 342:1034-1039.
21. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
22. Hetland G., Moen O., Bergh K., Hogasen K., Hack C.E., Mollnes T.E., Fosse E. Both plasma- and leukocyte-associated C5a are essential for assessment of C5a generation in vivo. Ann. Thorac. Surg. 1997, 63:1076-1080.
23. Humayun S., Gohar M., Volkening K., Moisse K., Leystra-Lantz C., Mepham J., McLean J., Strong M.J. The complement factor C5a receptor is upregulated in NFL-/- mouse motor neurons. J. Neuroimmunol. 2009, 210:52-62.
24. Ingersoll S.A., Martin C.B., Barnum S.R., Martin B.K. CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model. Mol. Immunol. 2010, 48:219-230.
25. Jacob A., Hack B., Chiang E., Garcia J.G., Quigg R.J., Alexander J.J. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 2010, 24:1682-1688.
26. Klos A., Wende E., Wareham K.J., Monk P.N. International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 2013, 65:500-543.
27. Lasiene J., Yamanaka K. Glial cells in amyotrophic lateral sclerosis. Neurol. Res. Int. 2011, 2011:718987.
28. Lee J.D., Kamaruzaman N.A., Fung J.N., Taylor S.M., Turner B.J., Atkin J.D., Woodruff T.M., Noakes P.G. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 2013, 10:119.
29. Li R., Coulthard L.G., Wu M.C., Taylor S.M., Woodruff T.M. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 2013, 27:855-864.
30. Lobsiger C.S., Boillée S., Pozniak C., Khan A.M., McAlonis-Downes M., Lewcock J.W., Cleveland D.W. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E4385-E4392.
31. Manthey H.D., Woodruff T.M., Taylor S.M., Monk P.N. Complement component 5a (C5a). Int. J. Biochem. Cell Biol. 2009, 41:2114-2117.
32. McCombe P.A., Henderson R.D. Effects of gender in amyotrophic lateral sclerosis. Gend. Med. 2010, 7:557-570.
33. McCombe P.A., Henderson R.D. The role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med. 2011, 11:246-254.
34. McGeer P.L., McGeer E.G., Kawamata T., Yamada T., Akiyama H. Reactions of the immune system in chronic degenerative neurological diseases. Can. J. Neurol. Sci. 1991, 18:376-379.
35. Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2012, 3:CD001447.
36. Mollnes T.E., Garred P., Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin. Exp. Immunol. 1988, 73:484-488.
37. Nagaki K., Hiramatsu S., Inai S., Sasaki A. The effect of aging on complement activity (CH50) and complement protein levels. J. Clin. Lab. Immunol. 1980, 3:45-50.
38. Oikonomopoulou K., Ricklin D., Ward P.A., Lambris J.D. Interactions between coagulation and complement-their role in inflammation. Semin. Immunopathol. 2012, 34:151-165.
39. Okusawa S., Yancey K.B., van der Meer J.W., Endres S., Lonnemann G., Hefter K., Frank M.M., Burke J.F., Dinarello C.A., Gelfand J.A. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J. Exp. Med. 1988, 168:443-448.
40. Oppermann M., Gotze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994, 82:516-521.
41. Pavlovski D., Thundyil J., Monk P.N., Wetsel R.A., Taylor S.M., Woodruff T.M. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 2012, 26:3680-3690.
42. Pehar M., Vargas M.R., Cassina P., Barbeito A.G., Beckman J.S., Barbeito L. Complexity of astrocyte-motor neuron interactions in amyotrophic lateral sclerosis. Neurodegener. Dis. 2005, 2:139-146.
43. Pfeifer P.H., Kawahara M.S., Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin. Chem. 1999, 45:1190-1199.
44. Reis E.S., Chen H., Sfyroera G., Monk P.N., Kohl J., Ricklin D., Lambris J.D. C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay. J. Immunol. 2012, 189:4797-4805.
45. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256-1264.
46. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65(Suppl. 1):S3-S9.
47. Sarma J.V., Ward P.A. The complement system. Cell Tissue Res. 2011, 343:227-235.
48. Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., de Carvalho M., Ince P.G., Lin C., Miller R.G., Mitsumoto H., Nicholson G., Ravits J., Shaw P.J., Swash M., Talbot K., Traynor B.J., Van den Berg L.H., Veldink J.H., Vucic S., Kiernan M.C. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013, 12:310-322.
49. Woodruff T.M., Strachan A.J., Sanderson S.D., Monk P.N., Wong A.K., Fairlie D.P., Taylor S.M. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001, 25:171-177.
50. Woodruff T.M., Costantini K.J., Crane J.W., Atkin J.D., Monk P.N., Taylor S.M., Noakes P.G. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 2008, 181:8727-8734.
51. Woodruff T.M., Costantini K.J., Taylor S.M., Noakes P.G. Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. Adv. Exp. Med. Biol. 2008, 632:143-158.
52. Woodruff T.M., Ager R.R., Tenner A.J., Noakes P.G., Taylor S.M. The role of the complement system and the activation fragment C5a in the central nervous system. Neruomol. Med. 2010, 12:179-192.
53. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 2011, 48:1631-1642.
54. Woodruff T.M., Lee J.D., Noakes P.G. Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E3-E4.
55. Yoshida S., Mulder D.W., Kurland L.T., Chu C.P., Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 1986, 5:61-70.
56. Zhao W., Beers D.R., Appel S.H. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013, 8:888-899.